For more than a decade, Gilead Sciences has been a leader in the development of antiretroviral therapy for HIV/AIDS. Gilead researchers have developed 11 commercially available HIV medications and are advancing a robust pipeline of next-generation therapeutic options.
Recognizing that the greatest need for HIV treatment is in the least-developed parts of the world, the company has put in place innovative programs and partnerships to expand global access to its medicines. Today, 12.5 million people are receiving Gilead HIV therapies in low- and middle-income countries.
People living with HIV estimated to be on Gilead-based treatment in developing countries.
Receiving licensed generics.
Decline in the lowest price for tenofovir disoproxil fumarate (TDF) since 2006
Developing countries have registered Truvada® (emtricitabine/TDF) for pre-exposure prophylaxis (PrEP)
Reducing HIV Among Young Women and Girls
Girls and young women account for 71 percent of new HIV infections among adolescents in sub-Saharan Africa. Through the DREAMS initiative, which is led by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), we provide funding for PrEP with the goal of helping young women to stay HIV-free. In its first year, DREAMS reached one million adolescent girls and young women and saw a 25 to 40 percent reduction in new HIV diagnoses in 65 percent of DREAMS districts.
Piloting Test-and-Treat in Rural Tanzania
In Tanzania, just 62 percent of people living with HIV are on treatment, while an estimated 30 percent are unaware of their infection. We partnered with the Vatican and the local Catholic diocese in the Shinyanga and Simiyu regions of northern Tanzania to reach people living with HIV and connect them to care. The program has now tested more than 112,000 people, brought treatment to more than 3,000 adults and children and helped prevent mother-to-child transmission of HIV for approximately 200 babies. Through this work, the program aims to help lower the community's viral load and slow HIV transmission.